Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard H Ko

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Frontiers in Pediatrics|February 22, 2017
Venous Thromboembolism in Children with Cancer and Blood DisordersRichard H Ko, Courtney D Thornburg
Thrombosis Research|February 20, 2013
A novel approach for detecting hypercoagulability utilizing thromboelastographyRichard H Ko, Lingyun Ji, Guy Young
Seminars in Fetal & Neonatal Medicine|January 19, 2016
The bleeding newborn: A review of presentation, diagnosis, and managementJulie Jaffray, Guy Young, Richard H Ko
Thrombosis Research|August 5, 2014
FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic eventsRichard H Ko, Carlo Michieli, Jessica L Lira, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 5, 2022
A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical proceduresMiguel Escobar, Amy Dunn, Doris Quon, et al.
Pediatric Blood & Cancer|December 28, 2021
Markers of hypercoagulability in children with newly diagnosed acute lymphoblastic leukemiaRoxana Carmona, Hande Kizilocak, Elizabeth Marquez-Casas, et al.
Thrombosis Research|March 24, 2018
Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemiaSaskia Prasca, Roxana Carmona, Lingyun Ji, et al.
Research and Practice in Thrombosis and Haemostasis|March 13, 2023
Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxisSteven W Pipe, Ben Trzaskoma, Miranda Minhas, et al.
Research and Practice in Thrombosis and Haemostasis|August 4, 2023
Corrigendum to 'Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis' [Research and Practice in Thrombosis and Haemostasis, Volume 7, Issue 2, February 2023, 100077]Steven W Pipe, Ben Trzaskoma, Miranda Minhas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2009
Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium studyRichard H Ko, Lingyun Ji, Phillip Barnette, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Frontiers in Pediatrics|February 22, 2017
Venous Thromboembolism in Children with Cancer and Blood DisordersRichard H Ko, Courtney D Thornburg
Thrombosis Research|February 20, 2013
A novel approach for detecting hypercoagulability utilizing thromboelastographyRichard H Ko, Lingyun Ji, Guy Young
Seminars in Fetal & Neonatal Medicine|January 19, 2016
The bleeding newborn: A review of presentation, diagnosis, and managementJulie Jaffray, Guy Young, Richard H Ko
Thrombosis Research|August 5, 2014
FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic eventsRichard H Ko, Carlo Michieli, Jessica L Lira, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 5, 2022
A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical proceduresMiguel Escobar, Amy Dunn, Doris Quon, et al.
Pediatric Blood & Cancer|December 28, 2021
Markers of hypercoagulability in children with newly diagnosed acute lymphoblastic leukemiaRoxana Carmona, Hande Kizilocak, Elizabeth Marquez-Casas, et al.
Thrombosis Research|March 24, 2018
Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemiaSaskia Prasca, Roxana Carmona, Lingyun Ji, et al.
Research and Practice in Thrombosis and Haemostasis|March 13, 2023
Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxisSteven W Pipe, Ben Trzaskoma, Miranda Minhas, et al.
Research and Practice in Thrombosis and Haemostasis|August 4, 2023
Corrigendum to 'Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis' [Research and Practice in Thrombosis and Haemostasis, Volume 7, Issue 2, February 2023, 100077]Steven W Pipe, Ben Trzaskoma, Miranda Minhas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2009
Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium studyRichard H Ko, Lingyun Ji, Phillip Barnette, et al.
Pageof 2